Israel Charo
Corporate Officer/Principal bei The University of California, San Francisco
Profil
Israel Charo is a Professor at The University of California, San Francisco since 1991.
He previously worked as a Senior Vice President-Research at ChemoCentryx, Inc. and as a Venture Partner at Bay City Capital LLC.
He completed his undergraduate degree at Stony Brook University, his graduate degree at the University of California, Berkeley, and his doctorate at the State University of New York at Downstate Medical Center.
Aktive Positionen von Israel Charo
| Unternehmen | Position | Beginn |
|---|---|---|
| The University of California, San Francisco | Corporate Officer/Principal | 01.01.1991 |
Ehemalige bekannte Positionen von Israel Charo
| Unternehmen | Position | Ende |
|---|---|---|
| CHEMOCENTRYX, INC. | Technik-/Wissenschafts-/F&E-Leiter | - |
Bay City Capital LLC
 Bay City Capital LLC Investment ManagersFinance Bay City Capital LLC (Bay City Capital) is a venture capital firm founded in 1997 by Fred Craves, John Diekman, and Thomas Pritzker. The firm is headquartered in California, United States. | Private Equity Investor | 15.12.2010 |
Ausbildung von Israel Charo
| State University of New York at Downstate Medical Center | Doctorate Degree |
| Stony Brook University | Undergraduate Degree |
| University of California, Berkeley | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 2 |
|---|---|
Bay City Capital LLC
Bay City Capital LLC Investment ManagersFinance Bay City Capital LLC (Bay City Capital) is a venture capital firm founded in 1997 by Fred Craves, John Diekman, and Thomas Pritzker. The firm is headquartered in California, United States. | Finance |
ChemoCentryx, Inc.
 ChemoCentryx, Inc. Pharmaceuticals: MajorHealth Technology ChemoCentryx, Inc. is a biopharmaceutical company, which engages in the development and commercialization of medicines. It focuses on inflammatory disorders, autoimmune diseases, and cancer. Its drug candidates such as Avacopan and CCX140, selectively blocks a specific chemoattractant receptor, leaving the rest of the immune system intact. The company was founded by Thomas J. Schall in 1997 and is headquartered in San Carlos, CA. | Health Technology |
